Self-reported compliance with topical cyclosporine emulsion 0.05% and onset of the effects of increased tear production as assessed through patient surveys

Clinical Therapeutics

Volumn 28, Issue 11, 2006, Pages 1848-1856

  Trattler, William ^a   Katsev, Douglas ^b   Kerney, Donna ^c  

^a Center for Excellence in Eye Care Florida   (United States)

^b Sansurn Santa Barbara Medical Foundation   (United States)

^c InfoMedics Inc   (United States)

Author keywords

compliance; cyclosporine ophthalmic emulsion; dry eye; keratoconjunctivitis sicca

Indexed keywords

CYCLOSPORIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRY EYE; EMULSION; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; LACRIMATION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT IDENTIFICATION; PHYSICIAN; PRESCRIPTION; QUESTIONNAIRE; SATISFACTION; SELF REPORT;

ADULT; AGED; CYCLOSPORINE; DATA COLLECTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATOCONJUNCTIVITIS SICCA; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PATIENT COMPLIANCE; RECOVERY OF FUNCTION; TIME FACTORS;

EID: 33845957897     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.11.016     Document Type: Article

References (19)

1. Pflugfelder S.C. Anti inflammatory therapy ford ry eye. Am J Ophthalmol. 137 (2004) 337-342
2. Schein O.D., Tielsch J.M., Munoz B., et al. Relation between signs and symptoms of dry eye in the elderly. A populationbased perspective. Ophthalmology 104 (1997) 1395-1401
3. Schaumberg D.A., Sullivan D.A., Buring J.E., and Dana M.R. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 136 (2003) 318-326
4. Wilson S.E. Inflammation: A unifying theory for the origin of dry eye syndrome. Manag Care. 12 Suppl 12 (2003) 14-19
5. Begley C.G., Chalmers R.L., Abetz L., et al. The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci. 44 (2003) 4753-4761
6. De Paiva C.S., Chen Z., Koch D.D., et al. The incidence and risk factors for developing dry eye after myopic LASIK. Am J Ophthalmol. 141 (2006) 438-445
7. Perry H.D., and Donnenfeld E.D. Dry eye diagnosis and management in 2004. Curr Opin Ophthalmol 15 (2004) 299-304
8. New Orleans, La. Perry H.D., Donnenfeld E.D., Perry A.R., et al. Evaluation of topical cyclosporine. A 0.05% for the treatment of dry eye disease. Paper presented at: Annual Meeting of the American Academy of Ophthalmology (October 23-26, 2004)
9. O'Brien P.D., and Collum L.M. Dry eye: Diagnosis and current treatment strategies. Curr Allerg Asthma Rep. 4 (2004) 314-319
10. Perry H.D., and Donnenfeld E.D. Topical 0.05% cyclosporin in the treatment of dry eye. Expert Opin Pharmacother 5 (2004) 2099-2107
11. [published correction appears in Ophthalmology. 2000;107:1220]. Sall K., Stevenson O.D., Mundorf T.K., Reis B.L., and CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 107 (2000) 631-639
12. Stevenson D., Tauber J., Reis B.L., and Cyclosporin A Phase 2 Study Group. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to severe dry eye disease: A dose-ranging, randomized trial. Ophthalmology 107 (2000) 967-974
13. Stonecipher K., Perry H.D., Gross R.H., and Kerney D.L. The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca. Curr Med Res Opin. 21 (2005) 1057-1063
14. Chaufan C. Patient compliance: In search of the real question in diabetes care. Am Fam Physician 61 (2000) 644-647
15. Oparil S., and Calhoun D.A. Managing the patient with hardto-control hypertension. Am Fam Physician 57 (1998) 1007-1014
16. Oparil S., and Calhoun D.A. Managing the patient with hardto-control hypertension. Am Fam Physician 57 (1998) 1019-1020
17. Cushman W.C., Reda D.J., Perry H.M., et al., Department of Veterans Affairs Cooperative Study Group on Anti hypertensive Agents. Regional and racial differ ences in response to anti hypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Arch Intern Med. 160 (2000) 825-831
18. Dezii C.M. Medication noncompliance: What is the problem?. Manag Care 9 Suppl 9 (2000) 7-12
19. Tauber J., and Cyclosporine Study Group. A dose-ranging clinical trial to assess the safety and efficacy of cyclosporine ophthalmic emulsion in patients with keratoconjunctivitis sicca. Adv Exp Med Biol. 438 (1998) 969-972